Roberto Hernando, MD
Psychiatry · Miami, FLNPI 1811985708
Payments from drug & device makers
Across 715 payments — averaging $606.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$420K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $6K from 17 others
What the payments were for
- Food & beverage$13,62398%
- Education$2532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 10 | $420,117 |
| AbbVie(2 entities) | 119 | $1,718 |
| Takeda Pharmaceuticals U.S.A., Inc. | 73 | $1,638 |
| Otsuka America Pharmaceutical, Inc. | 71 | $1,448 |
| Lundbeck LLC | 67 | $1,353 |
| Teva Pharmaceuticals USA, Inc. | 67 | $1,235 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $1,133 |
| Alkermes, Inc. | 57 | $1,071 |
| Sunovion Pharmaceuticals Inc. | 48 | $838 |
| Johnson & Johnson | 38 | $746 |
| Neurocrine Biosciences, Inc. | 30 | $724 |
| Almatica Pharma LLC | 28 | $576 |
| Vanda Pharmaceuticals Inc. | 26 | $518 |
| Axsome Therapeutics, Inc. | 11 | $240 |
| Bausch Health US, LLC | 6 | $121 |
| Indivior Inc. | 3 | $79 |
| Merck | 3 | $72 |
| Shire North American Group Inc | 3 | $60 |
| Tris Pharma Inc | 2 | $42 |
| Neos Therapeutics, LP | 2 | $31 |
| Luye Pharma (USA) Ltd. | 1 | $24 |
| Tempus AI, Inc | 1 | $23 |
| Livanova USA, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$433,828 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 34 | $275,061 |
| RexultiBrexpiprazole | 55 | $94,315 |
| VraylarCariprazine Hcl | 65 | $91,546 |
| AristadaAripiprazole Lauroxil | 37 | $81,306 |
| FanaptIloperidone | 22 | $79,624 |
| TrintellixVortioxetine Hydrobromide | 137 | $71,882 |
| Lurasidone Hcl | 134 | $27,748 |
| Effexor XrVenlafaxine Hcl | 17 | $27,526 |
| Aripiprazole | 272 | $23,767 |
| Quetiapine Fumarate | 1,060 | $15,371 |
| Trazodone Hcl | 953 | $13,326 |
| Clonazepam | 1,343 | $12,580 |
| Mirtazapine | 642 | $10,760 |
| Chlorpromazine Hcl | 48 | $10,256 |
| BelsomraSuvorexant | 22 | $9,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $724 | $275,06134 claims |
| AbbVieVraylar, Fetzima | $1,718 | $98,15878 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,448 | $94,31555 claims |
| Alkermes, Inc.Aristada | $1,071 | $81,30637 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $518 | $79,62422 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,638 | $71,882137 claims |
| MerckBelsomra | $72 | $9,85322 claims |
| Axsome Therapeutics, Inc.Auvelity | $240 | $7,43611 claims |
| Almatica Pharma LLCSertraline Hcl | $576 | $2,353461 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.